OPKO Health, Inc. (OPK)
USD 1.46
(-4.58%)
USD 1.46
(-4.58%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 326.56 Million USD | 52.96% |
| 2022 | 213.5 Million USD | 13.62% |
| 2021 | 187.9 Million USD | -15.36% |
| 2020 | 222 Million USD | 5.11% |
| 2019 | 211.2 Million USD | 568.35% |
| 2018 | 31.6 Million USD | -80.0% |
| 2017 | 157.99 Million USD | 261.53% |
| 2016 | 43.7 Million USD | -11.54% |
| 2015 | 49.4 Million USD | -62.43% |
| 2014 | 131.5 Million USD | -42.26% |
| 2013 | 227.74 Million USD | 904.34% |
| 2012 | 22.67 Million USD | 158.95% |
| 2011 | 8.75 Million USD | -40.39% |
| 2010 | 14.69 Million USD | -25.29% |
| 2009 | 19.66 Million USD | 64.34% |
| 2008 | 11.96 Million USD | -15.95% |
| 2007 | 14.23 Million USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 202 Thousand USD | 0.0% |
| 2001 | 202 Thousand USD | 61.6% |
| 2000 | 125 Thousand USD | -7.41% |
| 1999 | 135 Thousand USD | -32.5% |
| 1998 | 200 Thousand USD | 100.0% |
| 1997 | 100 Thousand USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 419.57 Million USD | 28.48% |
| 2024 Q2 | 269.44 Million USD | -35.78% |
| 2023 Q2 | 295.67 Million USD | 39.93% |
| 2023 Q1 | 211.3 Million USD | -1.03% |
| 2023 Q4 | 326.56 Million USD | 53.1% |
| 2023 Q3 | 213.3 Million USD | -27.86% |
| 2023 FY | 326.56 Million USD | 52.96% |
| 2022 Q2 | 282.35 Million USD | 1.02% |
| 2022 FY | 213.5 Million USD | 13.62% |
| 2022 Q3 | 292.22 Million USD | 3.5% |
| 2022 Q4 | 213.5 Million USD | -26.94% |
| 2022 Q1 | 279.5 Million USD | 48.75% |
| 2021 FY | 187.9 Million USD | -15.36% |
| 2021 Q1 | 293.41 Million USD | 32.17% |
| 2021 Q2 | 250.47 Million USD | -14.63% |
| 2021 Q3 | 244.29 Million USD | -2.47% |
| 2021 Q4 | 187.9 Million USD | -23.09% |
| 2020 Q4 | 222 Million USD | -20.17% |
| 2020 Q3 | 278.09 Million USD | -16.0% |
| 2020 Q2 | 331.06 Million USD | 4.87% |
| 2020 Q1 | 315.69 Million USD | 49.48% |
| 2020 FY | 222 Million USD | 5.11% |
| 2019 Q3 | 314.16 Million USD | -3.26% |
| 2019 FY | 211.2 Million USD | 568.35% |
| 2019 Q2 | 324.74 Million USD | 59.42% |
| 2019 Q1 | 203.7 Million USD | 544.62% |
| 2019 Q4 | 211.2 Million USD | -32.77% |
| 2018 Q3 | 208.75 Million USD | -0.48% |
| 2018 FY | 31.6 Million USD | -80.0% |
| 2018 Q4 | 31.6 Million USD | -84.86% |
| 2018 Q2 | 209.74 Million USD | 147.05% |
| 2018 Q1 | 84.9 Million USD | -46.26% |
| 2017 Q4 | 157.99 Million USD | 4.56% |
| 2017 FY | 157.99 Million USD | 261.53% |
| 2017 Q1 | 103.32 Million USD | 136.45% |
| 2017 Q2 | 132.46 Million USD | 28.2% |
| 2017 Q3 | 151.09 Million USD | 14.06% |
| 2016 Q1 | 149.91 Million USD | 203.48% |
| 2016 FY | 43.7 Million USD | -11.54% |
| 2016 Q4 | 43.7 Million USD | -15.15% |
| 2016 Q3 | 51.5 Million USD | -52.78% |
| 2016 Q2 | 109.07 Million USD | -27.25% |
| 2015 Q4 | 49.4 Million USD | -66.01% |
| 2015 Q2 | 125.95 Million USD | 2.85% |
| 2015 FY | 49.4 Million USD | -62.43% |
| 2015 Q1 | 122.46 Million USD | -6.87% |
| 2015 Q3 | 145.35 Million USD | 15.41% |
| 2014 Q4 | 131.5 Million USD | 1.19% |
| 2014 Q1 | 238.93 Million USD | 4.91% |
| 2014 FY | 131.5 Million USD | -42.26% |
| 2014 Q2 | 133.71 Million USD | -44.04% |
| 2014 Q3 | 129.95 Million USD | -2.81% |
| 2013 Q2 | 208.93 Million USD | -5.2% |
| 2013 FY | 227.74 Million USD | 904.34% |
| 2013 Q4 | 227.74 Million USD | 0.44% |
| 2013 Q3 | 226.74 Million USD | 8.52% |
| 2013 Q1 | 220.39 Million USD | 871.91% |
| 2012 Q3 | 21.36 Million USD | 46.61% |
| 2012 Q4 | 22.67 Million USD | 6.15% |
| 2012 Q1 | 14.19 Million USD | 62.09% |
| 2012 FY | 22.67 Million USD | 158.95% |
| 2012 Q2 | 14.57 Million USD | 2.66% |
| 2011 Q3 | 12.54 Million USD | -14.09% |
| 2011 Q1 | 14.55 Million USD | -0.94% |
| 2011 FY | 8.75 Million USD | -40.39% |
| 2011 Q4 | 8.75 Million USD | -30.21% |
| 2011 Q2 | 14.6 Million USD | 0.36% |
| 2010 Q1 | 16.69 Million USD | -15.12% |
| 2010 FY | 14.69 Million USD | -25.29% |
| 2010 Q4 | 14.69 Million USD | 71.53% |
| 2010 Q3 | 8.56 Million USD | 40.16% |
| 2010 Q2 | 6.11 Million USD | -63.39% |
| 2009 FY | 19.66 Million USD | 64.34% |
| 2009 Q1 | 17.32 Million USD | 44.78% |
| 2009 Q3 | 14.93 Million USD | 2.46% |
| 2009 Q4 | 19.66 Million USD | 31.62% |
| 2009 Q2 | 14.58 Million USD | -15.83% |
| 2008 Q1 | 13.7 Million USD | -3.74% |
| 2008 Q3 | 11.98 Million USD | 1.05% |
| 2008 Q4 | 11.96 Million USD | -0.13% |
| 2008 FY | 11.96 Million USD | -15.95% |
| 2008 Q2 | 11.85 Million USD | -13.48% |
| 2007 Q2 | 7.48 Million USD | 0.88% |
| 2007 Q3 | 10.95 Million USD | 46.33% |
| 2007 Q1 | 7.42 Million USD | 0.0% |
| 2007 Q4 | 14.23 Million USD | 29.92% |
| 2007 FY | 14.23 Million USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2003 Q1 | 179 Thousand USD | -11.39% |
| 2003 Q2 | 156 Thousand USD | -12.85% |
| 2003 Q3 | 132 Thousand USD | -15.38% |
| 2003 Q4 | - USD | -100.0% |
| 2003 FY | - USD | -100.0% |
| 2002 Q2 | 239 Thousand USD | -8.43% |
| 2002 Q3 | 217 Thousand USD | -9.21% |
| 2002 Q4 | 202 Thousand USD | -6.91% |
| 2002 FY | 202 Thousand USD | 0.0% |
| 2002 Q1 | 261 Thousand USD | 29.21% |
| 2001 Q3 | - USD | -100.0% |
| 2001 Q4 | 202 Thousand USD | 0.0% |
| 2001 FY | 202 Thousand USD | 61.6% |
| 2001 Q1 | 843 Thousand USD | 574.4% |
| 2001 Q2 | 812 Thousand USD | -3.68% |
| 2000 FY | 125 Thousand USD | -7.41% |
| 2000 Q4 | 125 Thousand USD | 0.0% |
| 2000 Q3 | - USD | -100.0% |
| 2000 Q2 | 125 Thousand USD | 0.0% |
| 2000 Q1 | 125 Thousand USD | -7.41% |
| 1999 Q4 | 135 Thousand USD | 35.0% |
| 1999 FY | 135 Thousand USD | -32.5% |
| 1999 Q2 | 200 Thousand USD | -81.82% |
| 1999 Q1 | 1.1 Million USD | 450.0% |
| 1999 Q3 | 100 Thousand USD | -50.0% |
| 1998 FY | 200 Thousand USD | 100.0% |
| 1998 Q4 | 200 Thousand USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q3 | - USD | -100.0% |
| 1998 Q1 | - USD | -100.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q4 | 100 Thousand USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | 100 Thousand USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 426 Thousand USD | -76558.216% |
| Applied DNA Sciences, Inc. | 1.23 Million USD | -26283.467% |
| Aspira Women's Health Inc. | 2.26 Million USD | -14311.474% |
| Biodesix, Inc. | 60.69 Million USD | -438.076% |
| BioNexus Gene Lab Corp. | 133.39 Thousand USD | -244709.775% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -20586.427% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -20586.427% |
| Bionano Genomics, Inc. | 87.94 Million USD | -271.319% |
| CareDx, Inc | 34.22 Million USD | -854.28% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 15.31 Million USD | -2033.011% |
| DarioHealth Corp. | 29.54 Million USD | -1005.46% |
| Exact Sciences Corporation | 2.55 Billion USD | 87.217% |
| Fulgent Genetics, Inc. | 14.9 Million USD | -2090.676% |
| Guardant Health, Inc. | 1.35 Billion USD | 75.877% |
| ICON Public Limited Company | 3.93 Billion USD | 91.708% |
| IDEXX Laboratories, Inc. | 947.88 Million USD | 65.548% |
| Illumina, Inc. | 2.26 Billion USD | 85.563% |
| Intelligent Bio Solutions Inc. | 871.44 Thousand USD | -37374.066% |
| iSpecimen Inc. | 196.24 Thousand USD | -166307.126% |
| Standard BioTools Inc. | 98.21 Million USD | -232.516% |
| MDxHealth SA | 41.26 Million USD | -691.383% |
| 23andMe Holding Co. | 76.51 Million USD | -326.797% |
| Medpace Holdings, Inc. | 142.12 Million USD | -129.777% |
| Myriad Genetics, Inc. | 145 Million USD | -125.217% |
| Mainz Biomed B.V. | 7.42 Million USD | -4300.669% |
| ENDRA Life Sciences Inc. | 394.4 Thousand USD | -82699.573% |
| NeoGenomics, Inc. | 611.67 Million USD | 46.612% |
| Neogen Corporation | 906.23 Million USD | 63.965% |
| Inotiv, Inc. | 417.64 Million USD | 21.807% |
| Natera, Inc. | 441.99 Million USD | 26.116% |
| OpGen, Inc. | 13.04 Million USD | -2403.614% |
| Psychemedics Corporation | 2.29 Million USD | -14110.792% |
| Prenetics Global Limited | 2.36 Million USD | -13682.631% |
| Prenetics Global Limited | 2.36 Million USD | -13682.631% |
| Precipio, Inc. | 1.11 Million USD | -29162.007% |
| Personalis, Inc. | 48.96 Million USD | -566.974% |
| RadNet, Inc. | 1.49 Billion USD | 78.099% |
| Sera Prognostics, Inc. | 1.85 Million USD | -17476.103% |
| Sotera Health Company | 2.32 Billion USD | 85.967% |
| Neuronetics, Inc. | 62.47 Million USD | -422.72% |
| Star Equity Holdings, Inc. | 3.6 Million USD | -8948.601% |
| Star Equity Holdings, Inc. | 3.6 Million USD | -8948.601% |
| Trinity Biotech plc | 67.42 Million USD | -384.322% |
| T2 Biosystems, Inc. | 49.49 Million USD | -559.752% |
| Twist Bioscience Corporation | 94.06 Million USD | -247.154% |
| Exagen Inc. | 23.72 Million USD | -1276.687% |